-
In step with the rapid transformation of startup business models, seed financing continues to evolve. Join
#JLABSSD Head Sanjay Mistry today to learn more about key changes that can impact life science innovators in 2020.#BiotechShowcase#JPM20pic.twitter.com/eZjhmhgd2t -
#JLABSSD resident Entos announces a new partnership! Their Fusogenix drug delivery platform will be used to develop nex gen therapies for inflammatory & autoimmune diseases https://jlabs.buzz/arn -
Not all funding is created equal – learn about non-dilutive $ sources and how you might get them at
#JLABSSD on Dec. 3rd. Register now https://bit.ly/2NDNgza -
Congratulations to Avidity Biosciences, a
#JLABSSD alumni, on their $35M research and licensing collaboration for their antibody-oligonucleotide technology! Under the new deal, they could receive additional funds of up to $405M in…https://lnkd.in/ecHt4Yp https://lnkd.in/e9aDyG4 -
It’s almost time! Tomorrow, come meet the
#JLABSSD team and learn about joining the JLABS @ San Diego community. See you there: https://meetjlabssd.splashthat.com/ pic.twitter.com/pz3Z1uox65
-
Show me your holiday cheer!
@chelsbells4@BritSab09#jlabssd pic.twitter.com/2JboUHmRAn -
Got a speech coming up soon? Get an insider tip from @johnbates in link below
https://executivespeakingsuccess.com/openings-closings …
Don't forget to be there in person for #jlabssd program 10.17 Register: https://jlabs.buzz/n0v pic.twitter.com/VIM7tZAu9M
-
Creating potentially life changing science is hard work – but, you don’t have to do it alone! Get a feel for what it’s like to be part of the
#JLABSSD community & meet the team 1/29
https://meetjlabssd.splashthat.com/ pic.twitter.com/zJuEtmPHSN
-
50% chance of showers, 100% chance of funds -
#JLABSSD resident Locana announces a $55M series A round for their RNA targeting#genetherapyhttp://jlabs.buzz/ltt -
Should you hire a grant writer?
Opinions are mixed - a good strategy is to write the grant yourself (nobody knows the science better!) and have an external advisor do a mock review #JLABSSD pic.twitter.com/LSWJzIgAVj
-
DYK almost 2x as many women die of lung cancer than breast cancer? *
#JLABSSD gathers leading researchers & innovators to talk breakthrough innovations 11/14 https://jlabs.tv/2JND051 *source: https://jlabs.tv/2PFtQLL pic.twitter.com/07CCDG55bP
-
Fall funding news for Avidity Biosciences - $100M raised to advance pioneering science to treat rare muscle disorders Troy Wilson is a terrific founder and now Sarah Boyce as CEO.
#JLABSSD#JLABSAlumnihttps://jlabs.tv/2qMK9fs -
Is your startup advancing science that could prevent biological, chemical or infectious disease threats? Apply to meet with
@BARDA by 9/5: http://bit.ly/33YcM8x#JLABSSD pic.twitter.com/RVuAtTby1c
-
From a handful companies at the start of
#JLABSSD in 2012, to 560+ globally today –@SDBusiness reflects on the purpose & impact of@JLABS on the innovation ecosystem in San Diego and beyondhttp://jlabs.buzz/g1h -
Progress towards late stage clinical development for
#JLABSSD alumni, EpicentRX - $35M series D announced to advance their cancer immunotherapy https://jlabs.tv/2Xcfp3q -
#JLABSSD Sanjay Mistry highlights@JLABS incubation model is no strings attached, offering mentorship, expertise, & a “community of companies” of shared learning among residents.#BiotechShowcase#JPM20pic.twitter.com/iGjXOWLVeH
-
Congratulations
#JLABSSD resident, Phoenix Molecular Designs who received clearance to enter Phase 1/1b clinical trials for PMD-026 an RSK inhibitor targeting advanced#breastcancer,read more:http://jlabs.buzz/3lq -
From cutting-edge immunotherapy to disease treatment through genomics - catch groundbreaking science addressing lung cancer at
#JLABSSD 11/14 https://jlabs.buzz/feeab -
Shout out to
#JLABSSD alumni Poseida who raised $142M on Series C round of funding. Congratulations!!#CART#GetMoney#Sandiego Read more:http://bit.ly/2GvutS1 -
Are you weighing the options of debt vs. equity in your startup’s finance strategy? Hear from experts from Correlation Ventures, Avidity Biosciences & SVB 2.27
#JLABSSD https://jlabs.tv/2Nm1h44 pic.twitter.com/kOMFH6LmKv
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.